These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 26086883

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
    Blanchet M, Sureau C, Labonté P.
    Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide.
    Okuyama-Dobashi K, Kasai H, Tanaka T, Yamashita A, Yasumoto J, Chen W, Okamoto T, Maekawa S, Watashi K, Wakita T, Ryo A, Suzuki T, Matsuura Y, Enomoto N, Moriishi K.
    Sci Rep; 2015 Nov 23; 5():17047. PubMed ID: 26592202
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
    Nio Y, Akahori Y, Okamura H, Watashi K, Wakita T, Hijikata M.
    Biochem Biophys Res Commun; 2018 Jun 27; 501(3):820-825. PubMed ID: 29723527
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.
    Li J, Zong L, Sureau C, Barker L, Wands JR, Tong S.
    J Virol; 2016 Sep 15; 90(18):8302-13. PubMed ID: 27384660
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
    Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T.
    Hepatology; 2014 May 15; 59(5):1726-37. PubMed ID: 24375637
    [Abstract] [Full Text] [Related]

  • 11. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
    König A, Yang J, Jo E, Park KHP, Kim H, Than TT, Song X, Qi X, Dai X, Park S, Shum D, Ryu WS, Kim JH, Yoon SK, Park JY, Ahn SH, Han KH, Gerlich WH, Windisch MP.
    J Hepatol; 2019 Aug 15; 71(2):289-300. PubMed ID: 31077792
    [Abstract] [Full Text] [Related]

  • 12. Interleukin 6 inhibits HBV entry through NTCP down regulation.
    Bouezzedine F, Fardel O, Gripon P.
    Virology; 2015 Jul 15; 481():34-42. PubMed ID: 25765005
    [Abstract] [Full Text] [Related]

  • 13. NTCP opens the door for hepatitis B virus infection.
    Yan H, Liu Y, Sui J, Li W.
    Antiviral Res; 2015 Sep 15; 121():24-30. PubMed ID: 26071008
    [Abstract] [Full Text] [Related]

  • 14. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.
    Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Zhao H, Lu M, Wu C, Chen X.
    Emerg Microbes Infect; 2018 Nov 21; 7(1):186. PubMed ID: 30459339
    [Abstract] [Full Text] [Related]

  • 15. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
    König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D.
    J Hepatol; 2014 Oct 21; 61(4):867-75. PubMed ID: 24845614
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T.
    J Hepatol; 2017 Apr 21; 66(4):685-692. PubMed ID: 27890789
    [Abstract] [Full Text] [Related]

  • 17. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
    Goh B, Choi J, Kang JA, Park SG, Seo J, Kim TY.
    J Pharm Biomed Anal; 2020 Jan 30; 178():112959. PubMed ID: 31722821
    [Abstract] [Full Text] [Related]

  • 18. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
    Yan H, Li W.
    Dig Dis; 2015 Jan 30; 33(3):388-96. PubMed ID: 26045274
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization.
    Fukano K, Oshima M, Tsukuda S, Aizaki H, Ohki M, Park SY, Wakita T, Wakae K, Watashi K, Muramatsu M.
    J Virol; 2021 Nov 23; 95(24):e0093821. PubMed ID: 34613794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.